Objectives: In the current study, we proposed to investigate neurological manifestations in patients with hematolymphoid neoplasms in a tertiary care centre in Kolkata

Materials and Methods: This was a prospective observational study from 1st February 2013 to 31^st January 2015 among newly diagnosed 194 consecutive eligible cases of hematolymphoid neoplasms attending Institute of Hematology and Transfusion Medicine and/or Department of Neurology, Medical College and Hospital, Kolkata. All the patients were subjected to detailed clinical, biochemical, electrophysiological and radiological investigations.

Results and Analysis: Overall 22% of total patients of hematolymphoid neoplasms with neurological manifestations had NM at presentation. 28%, 15% & 22% of patients with myeloma, leukemia, and lymphoma respectively had NM at presentation of their HN. Therapy related causes were more (78.8% of patients with neurological manifestations had therapy related complications) than directly disease related causes (28.8%) & indirectly disease related causes (24%). Various neurological manifestations were noted. Most common neurological manifestation in all groups was peripheral neuropathy (40% of total 194 patients). 58.5%, 33.3%, 27.5% of patients with myeloma, leukemia, lymphoma respectively developed neuropathy.

Conclusion: Hematolymphoid neoplasms affect both the central and peripheral nervous system and their manifestations can be varied. Most of the patients develop neurological manifestations only during and after therapy. Some patients also have neurological manifestations at presentation and these may be the sole presentation. Therapy leads to more neurological complications than other causes in patients with hematolymphoid neoplasms. Peripheral neuropathy is the commonest neurological manifestation in all groups and shows temporal relationship with therapy.

Keywords: hematolymphoid neoplasms, myeloma, leukemia, lymphoma, Peripheral neuropathy.

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood.2009 Jul 30; 114(5):937-51.
2. World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.13.
3. Martin, E., and Courville, C.B.: Hodgkin's Disease With Involvement of the
   Cranial Dura Mater , Bull Los Angeles Neurol Soc 1:145.
4. Winkelmann, W., and Moore, T.M.: Lymphogranulomatosis (Hodgkin's Disease
   of the Nervous System) , Arch Neurol Psychiat 45:304.
5. Malhotra P, Choudhary PP, Lal V, et al. Prevalence of peripheral neuropathy in multiple myeloma at initial diagnosis. Leuk Lymphoma 2011; 52: 2135–8.
6. Sonneveld P, Jongen Dealing with neuropathy in plasma-cell dyscrasias. Hematology Am Soc
   Hematol Educ Program 2010: 423–430.
7. Anderson H, Scarffe JH, Lambert M, et al. VAD chemotherapy – toxicity and efficacy – in patients with multiple myeloma and other lymphoid malignancies. Hematol Oncol 1987; 5: 213–222.
8. Lavoie Smith EM, Li L, Hutchinson RJ, Ho R, Burnette WB, Wells E, Bridges C, Renbarger J. Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs. 2013 Sep-Oct;36(5):E49-60.
9. Wood NL, Coltman CA. Localized primary extranodal Hodgkin's disease. Annals
   of Internal Medicine. 1973;78 (1):113–118.
10. Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2006 Mar;132(5):584-93.
11. Von Lilienfeld-Toal M, Hahn-Ast C, Furkert K, et al. A systematic review of phase II trials of thalidomide/ dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol. 2008; 81:247–252.
12. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006; 24:431– 436.
13. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357:2123–2132.
14. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113–20.
15. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005; 352:2487–2498.
16. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004 Oct;127(2):165-172.

Prasenjit Sengupta

Flat-4B, Landmark Apartment, 298,

NSC Bose Road, Kolkata-700047, West Bengal